PubMed COVID-19 Clinical Care

In addition to the original monovalent vaccines available for SARS-CoV-2, bivalent vaccines covering wild-type (WT) and Omicron BA.1 are also available. However, there is a lack of real-world data on the immunogenicity of bivalent vaccines as second

Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS-CoV-2 pandemic. Nirmatrelvir-an orally available inhibitor of the 3-chymotrypsin-like cysteine protease-has been shown to reduce the risk of progression to

No abstract

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via

Background This study aims to provide a better knowledge of COVID-19 that will aid in the formulation of future health policy by detailing the pathophysiology, case detection, and treatment, as well as management and prevention activities

CONCLUSION: The risk factors, identified in this study, can be used as significant independent predictors for developing MS post-COVID-19 vaccinations.

COVID-19 in the pediatric population is mostly asymptomatic. However, 1 out of 5 children presents non-specific neurologic symptoms such as headache, weakness, or myalgia. Furthermore, rarer forms of neurological diseases are increasingly being

5-Methylcytosine (m⁵C) is a widespread post-transcriptional RNA modification and is reported to be involved in manifold cellular responses and biological processes through regulating RNA metabolism. However, its regulatory role in antiviral innate

CONCLUSIONS: We report a case of nonepisodic AE after COVID-19 vaccination that was successfully treated with reslizumab.

To evaluate the effect of Nirmatrelvir-ritonavir therapy and COVID-19 vaccination on clinical outcomes of SARS-Cov-2 Omicron infection，we retrospectively analyzed the clinical data of 762 adult patients with confirmed Omicron BA2.2 variant infection